Randomized Phase II trial of Cyclophosphamide and the Oral Poly (ADP-ribose) Polymerase Inhibitor Veliparib in Patients with Recurrent, Advanced Triple-Negative Breast Cancer

BACKGROUND: In tumors carrying BRCA mutations, DNA damage caused by standard cytotoxic chemotherapy can be potentiated by poly [ADP-ribose] polymerase (PARP) inhibitors, leading to increased cell death through synthetic lethality. Individuals carrying mutations in BRCA have an increased incidence of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Invest New Drugs
Main Authors: Kummar, Shivaani, Wade, James L., Oza, Amit M., Sullivan, Daniel, Chen, Alice P., Gandara, David R., Ji, Jiuping, Kinders, Robert J., Wang, Lihua, Allen, Deborah, Coyne, Geraldine O’Sullivan, Steinberg, Seth M., Doroshow, James H.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4860030/
https://ncbi.nlm.nih.gov/pubmed/26996385
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-016-0335-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados